Latest Watson Pharmaceuticals Inc. Stories
PARSIPPANY, N.J., Jan. 24, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. today announced that the company has adopted Actavis, Inc. (NYSE: ACT) as its new global name and will today begin trading under a new symbol -- ACT -- on the New York Stock Exchange. The company first announced its intention to change its name last year, following its acquisition of the Actavis Group. The combination created the world's third largest generic pharmaceutical company, with anticipated...
PARSIPPANY, N.J., Jan. 23, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets. Actavis' ANDA product is a generic version of the currently marketed formulation of Endo Health Solutions' Opana(®) ER,...
PARSIPPANY, N.J., Jan. 23, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of Belgium-based Uteron Pharma SA for $150 million in cash up front, and up to $155 million in potential future milestone payments. The acquisition of Uteron expands Watson's Global Brands pipeline of Women's Health products including two potential near term global commercial opportunities in contraception and infertility, and one novel...
LONDON, January 18, 2013 /PRNewswire/ -- The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers in the past years and this trend is expected to go for some years to come. In 2012 alone, over 40 branded drugs with a $35 billion yearly sales tag have lost patent protection. StockCall has technical coverage on two of the biggest generic makers, Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI), which is...
PARSIPPANY, N.J., Jan. 11, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it will host an Investor Meeting on January 25, 2013 in New York. The meeting will begin at 8:00 a.m. EST and will be webcast simultaneously. The meeting will be hosted by Watson's executive leadership team and will offer an in-depth look into the combined company following the acquisition of the Actavis Group. Paul...
PARSIPPANY, N.J., Jan. 3, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc. - Florida has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for tranexamic acid tablets, the generic equivalent to Ferring Pharmaceuticals' Lysteda®. Watson intends to begin shipping the product immediately. Lysteda® is indicated for the treatment of cyclic heavy...
PARSIPPANY, N.J., Dec. 28, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis, Inc., which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market bortezomib. Actavis' ANDA product is a generic version of Millennium Pharmaceuticals' Velcade( ®) (bortezomib), which is a proteasome inhibitor, for intravenous or subcutaneous administration,...
PARSIPPANY, N.J., Dec. 21, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 31st Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2013 at 7:30 am PST (10:30 am EST) at the Westin St. Francis Hotel, San Francisco, California. The presentation will be webcast live...
PARSIPPANY, N.J., Dec. 20, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2013 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top conference on Thursday, January 3, 2013 at 1:45 pm EST at the Goldman Sachs Conference Center in New York. The presentation will be...
PARSIPPANY, N.J., Nov. 14, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2012 Piper Jaffray Health Care Conference on Wednesday, November 28, 2012 at 11:00 am EST at the New York Palace Hotel in New York. The presentation will be webcast live and can be accessed on Watson...
